Advertisement


Jame Abraham, MD, on The JAVELIN and KEYNOTE-028 Study Results

2015 San Antonio Breast Cancer Symposium

Advertisement

Jame Abraham, MD, of the Cleveland Clinic, discusses findings on the use of avelumab, an anti–PD-L1 antibody, in patients with locally advanced or metastatic breast cancer, as well as the preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor–positive/HER2-negative disease (Abstracts S1-04, S5-07).



Related Videos

Breast Cancer

Lisa Carey, MD, and Sibylle Loibl, MD, PhD: Update on Metastatic Disease

Lisa A. Carey, MD, of the University of North Carolina, and Sibylle Loibl, MD, PhD, of the German Breast Group, discuss new data on palbociclib, new immunotherapy, and brain metastases (Abstract YR4).

Breast Cancer

Andrew Seidman, MD, and Seema Khan, MD, MPH on Controversies in the Management of DCIS

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discuss the session moderated by Dr. Khan on this important topic (Session ES8).

Breast Cancer
Cost of Care

Benjamin D. Smith, MD, on Mastectomy vs Lumpectomy: Complications and Costs

Benjamin D. Smith, MD, of the MD Anderson Cancer Center, discusses the higher complication rates and economic burdens of mastectomy plus reconstruction vs lumpectomy plus radiation in early breast cancer (Abstract S3-07).

Breast Cancer

Lisa Carey, MD, and Kathy Albain, MD, on Results of the SWOG-8814 Trial

Lisa A. Carey, MD, of the University of North Carolina, and Kathy S. Albain, MD, of Loyola University Medical Center, discuss molecular predictors of outcome on adjuvant CAF plus tamoxifen, vs tamoxifen in postmenopausal patients with estrogen receptor–positive, node-positive breast cancer (Abstract S3-02).

Breast Cancer

Jame Abraham, MD, on HER2-Positive Breast Cancer: Results of the BCIRG-006 Study

Jame Abraham, MD, of the Cleveland Clinic, discusses the 10-year follow-up of this trial, and the long-term benefit and safety of adding trastuzumab to the adjuvant treatment of HER2-positive early breast cancer (Abstract S5-04).

Advertisement

Advertisement




Advertisement